Interferon regulatory factor 1 (IRF-1) contributes to the pathological phenotype of VSMCs during atherosclerosis by increasing CCL19 transcription, whereas silencing IRF-1 inhibits angiotensin proliferation and migration and downregulates CCL19 expression, thereby suppressing atherosclerosis 32. This evidence concerns the gene CCL19 and atherosclerosis.